Although high-level evidence is currently lacking, noninferiority randomised controlled trials in predefined risk groups in non-muscle-invasive bladder cancer are under way to scientifically prove the safety of urinary biomarker-guided follow-up. To facilitate recommendations for clinical use, it is essential to comply with the EU certification for in vitro diagnostics and to demonstrate cost effectiveness.
European urology oncology. 2024 Sep 28 [Epub ahead of print]
Fredrik Liedberg, Paramananthan Mariappan, Paolo Gontero, EAU NMIBC Guideline Panel
Department of Urology, Skane University Hospital, Lund University, Malmö, Sweden. Electronic address: ., Edinburgh Bladder Cancer Surgery, University of Edinburgh, Western General Hospital, Edinburgh, UK., Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.